Objective In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy. Fields of science medical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicineoncologycolorectal cancer Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH-2011.1.1-2 - Genome-based biomarkers for patient stratification and pharmacogenomic strategies Call for proposal FP7-HEALTH-2011-two-stage See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator ROYAL COLLEGE OF SURGEONS IN IRELAND Address St stephen's green 123 2 Dublin Ireland See on map Region Ireland Northern and Western Border Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window EU contribution No data Participants (10) Sort alphabetically Sort by EU Contribution Expand all Collapse all VIB VZW Belgium EU contribution € 677 500,00 Address Rijvisschestraat 120 9052 Zwijnaarde - gent See on map Region Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Other funding No data EPIGENOMICS AG Germany EU contribution € 794 625,00 Address Kleine praesidentenstr 1 10178 Berlin See on map Region Berlin Berlin Berlin Links Contact the organisation Opens in new window Website Opens in new window Other funding No data SOMANTIX BV Netherlands EU contribution € 587 800,00 Address Professor bronkhorstlann 10-92 3723 MB Bilthoven See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data ONCOMARK LIMITED Ireland EU contribution € 697 800,00 Address 172 rathgar road rathgar Dublin 6 Dublin See on map Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG Netherlands EU contribution € 0,00 Address De boelelaan 1105 1081 HV Amsterdam See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Other funding No data RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG Germany EU contribution € 541 950,75 Address Seminarstrasse 2 69117 Heidelberg See on map Region Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Other funding No data UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN Ireland EU contribution € 634 800,00 Address Belfield 4 Dublin See on map Region Ireland Eastern and Midland Dublin Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Other funding No data CANCER TRIALS IRELAND COMPANY LIMITED BY GUARANTEE Ireland EU contribution € 277 200,00 Address Rcsi house, 121 st stephen's green D02 H903 Dublin 2 See on map Region Ireland Eastern and Midland Dublin Links Contact the organisation Opens in new window Website Opens in new window Other funding No data PINTAIL LTD Ireland EU contribution € 152 000,00 Address Springhill avenue 77 A94 K542 Blackrock See on map Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Other funding No data STICHTING VU Netherlands EU contribution € 436 200,00 Address De boelelaan 1105 1081 HV Amsterdam See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Other funding No data
